travel bans. south africa calling those moves unfair. pandemics are not about panicking, they re about policies, protocols and practice. and we are also monitoring this hour the market, the stock market as nervous investors as stocks stabilize after friday s fifth selloff. announcer: live from london, this is cnn newsroom with isa soares. hello, everyone. it is monday, november 29th. we begin with a global scramble where we ve contained the omicron variant. the world health organization has in the last hour or so come out with a technical statement saying the risk is very high. travelers from south africa take effect. g7 is set to hold talks later on the phone today. new form of omicron has been found in seven countries. the u.s. isn t alone in shutting its borders in an attempt to contain the variant. that has sparked anger in south africa where scientists have alerted the global community. while there are signs omicron is more infectious, we still don t know how b
Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant changes over the past decade. Marking a transition from a period of consolidation and valuation readjustment to one where the focus has shifted towards more sustainable and compliant operational practices. This transformation highlights a shift in the strategic approach adopted by pharmaceutical companies. Historically, the expansion strategies of many pharma companies were driven by optimistic powerpoint presentations forecasting market growth. However, this approach often overlooked the critical aspect of regulatory compliance, leading to various challenges. Over the years the Indian pharmaceutical industry has understood that regulatory compliance might be slightly more time consuming and also expensive but in long run it pays both for the real business growth and improving valuations. Will the industry remember the critical lesson is key.
Ajanta Pharma shares surged by 13.70% to reach a new high of ₹2,540 apiece following a strong performance in Q4 and full fiscal year. The company reported a 66% YoY jump in consolidated net profit in Q4 to ₹122 crore. For the full fiscal year (FY24), the net profit surged to ₹816 crore.
Kenneth Andrade, of Old Bridge Capital Management, emphasizes market breadth narrowing to specific stocks and commodity favoritism. He discusses challenges in the IT and defense sectors, PSU companies, and future businesses like Zomato and Paytm. Andrade says: "I am a firm believer that any company out there who gets pricing power will get price earning multiples. "